Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Holbrook Kohrt: In Memoriam (1977-2016).
Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A. Houot R, et al. Among authors: pachynski r. Clin Cancer Res. 2016 Jul 15;22(14):3695-6. doi: 10.1158/1078-0432.CCR-16-1181. Clin Cancer Res. 2016. PMID: 27422201 No abstract available.
Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
Wu Y, Terekhanova NV, Caravan W, Naser Al Deen N, Lal P, Chen S, Mo CK, Cao S, Li Y, Karpova A, Liu R, Zhao Y, Shinkle A, Strunilin I, Weimholt C, Sato K, Yao L, Serasanambati M, Yang X, Wyczalkowski M, Zhu H, Zhou DC, Jayasinghe RG, Mendez D, Wendl MC, Clark D, Newton C, Ruan Y, Reimers MA, Pachynski RK, Kinsinger C, Jewell S, Chan DW, Zhang H, Chaudhuri AA, Chheda MG, Humphreys BD, Mesri M, Rodriguez H, Hsieh JJ, Ding L, Chen F. Wu Y, et al. Among authors: pachynski rk. Nat Commun. 2023 Mar 27;14(1):1681. doi: 10.1038/s41467-023-37211-7. Nat Commun. 2023. PMID: 36973268 Free PMC article.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. Kohrt HE, et al. Among authors: pachynski r. Blood. 2011 Feb 24;117(8):2423-32. doi: 10.1182/blood-2010-08-301945. Epub 2010 Dec 30. Blood. 2011. Retraction in: Blood. 2019 Aug 15;134(7):658. doi: 10.1182/blood.2019002416 PMID: 21193697 Free PMC article. Retracted.
Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer.
Pachynski RK, Kim EH, Miheecheva N, Kotlov N, Ramachandran A, Postovalova E, Galkin I, Svekolkin V, Lyu Y, Zou Q, Cao D, Gaut J, Ippolito JE, Bagaev A, Bruttan M, Gancharova O, Nomie K, Tsiper M, Andriole GL, Ataullakhanov R, Hsieh JJ. Pachynski RK, et al. Clin Cancer Res. 2021 Jun 15;27(12):3478-3490. doi: 10.1158/1078-0432.CCR-20-4217. Epub 2021 Mar 26. Clin Cancer Res. 2021. PMID: 33771855
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. Yap TA, et al. Among authors: pachynski rk. Clin Cancer Res. 2022 Sep 1;28(17):3695-3708. doi: 10.1158/1078-0432.CCR-21-4256. Clin Cancer Res. 2022. PMID: 35511938 Free PMC article.
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Nguyen CB, Reimers MA, Perera C, Abida W, Chou J, Feng FY, Antonarakis ES, McKay RR, Pachynski RK, Zhang J, Reichert ZR, Palmbos PL, Caram MEV, Vaishampayan UN, Heath EI, Hopkins AC, Cieslik MP, Wu YM, Robinson DR, Baladandayuthapani V, Chinnaiyan AM, Alva AS. Nguyen CB, et al. Among authors: pachynski rk. Clin Cancer Res. 2024 Aug 1;30(15):3200-3210. doi: 10.1158/1078-0432.CCR-24-0400. Clin Cancer Res. 2024. PMID: 38787530 Clinical Trial.
72 results